US Medical Innovations — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

US Medical Innovations is a private medical device company pioneering cold atmospheric plasma technology for intraoperative cancer treatment. The company has achieved significant regulatory milestones, including FDA 510(k) clearance for its Canady Helios Cold Plasma Ablation System and FDA approval for a robotic surgical wrist device. Led by founder and CEO Dr. Jerome Canady, USMI is advancing a platform that aims to treat inoperable and advanced solid tumors, with early clinical data published from a Phase 1 trial.

OncologySurgical Oncology

Technology Platform

Cold Atmospheric Plasma (CAP) ablation technology engineered to generate a non-thermal plasma jet that delivers reactive species to selectively induce apoptosis in cancer cells while sparing healthy tissue.

Opportunities

The company has a first-mover advantage in FDA-cleared cold plasma surgery, targeting a vast surgical oncology market with an unmet need for non-thermal, selective ablation.

Expansion into robotic surgery and potential new indications for its plasma platform (e.g., wound care, sterilization) represent significant growth vectors.

Risk Factors

Major risks include the challenge of driving clinical adoption of a novel physics-based technology, the need for further large-scale trials to secure reimbursement, and intense competition in the capital-intensive surgical robotics market from established giants.

Competitive Landscape

USMI competes in the tumor ablation segment against thermal devices (radiofrequency, microwave) and in surgical robotics against Intuitive Surgical and others. Its primary differentiation is non-thermal, selective cell ablation via cold plasma, a unique mechanism with few direct competitors currently on the market.

More companies in Oncology (General) →More companies in United States →